473 related articles for article (PubMed ID: 25448046)
21. Quantitative investigation on the metabolism of 1,3-butadiene and of its oxidized metabolites in once-through perfused livers of mice and rats.
Filser JG; Bhowmik S; Faller TH; Hutzler C; Kessler W; Midpanon S; Pütz C; Schuster A; Semder B; Veereshwarayya V; Csanády GA
Toxicol Sci; 2010 Mar; 114(1):25-37. PubMed ID: 20007191
[TBL] [Abstract][Full Text] [Related]
22. Disposition of butadiene epoxides in Sprague-Dawley rats following exposures to 8000 ppm 1,3-butadiene: comparisons with tissue epoxide concentrations following low-level exposures.
Thornton-Manning JR; Dahl AR; Allen ML; Bechtold WE; Griffith WC; Henderson RF
Toxicol Sci; 1998 Feb; 41(2):167-73. PubMed ID: 9520352
[TBL] [Abstract][Full Text] [Related]
23. 1,3-butadiene: cancer, mutations, and adducts. Part I: Carcinogenicity of 1,2,3,4-diepoxybutane.
Henderson RF; Barr EB; Belinsky SA; Benson JM; Hahn FF; Ménache MG
Res Rep Health Eff Inst; 2000 Mar; (92):11-43; discussion 45-8. PubMed ID: 10925838
[TBL] [Abstract][Full Text] [Related]
24. Metabolism of 1,3-butadiene: inhalation pharmacokinetics and tissue dosimetry of butadiene epoxides in rats and mice.
Himmelstein MW; Turner MJ; Asgharian B; Bond JA
Toxicology; 1996 Oct; 113(1-3):306-9. PubMed ID: 8901914
[TBL] [Abstract][Full Text] [Related]
25. 1,3-Butadiene: toxicity and carcinogenicity in laboratory animals and in humans.
Melnick RL; Huff J
Rev Environ Contam Toxicol; 1992; 124():111-44. PubMed ID: 1732994
[TBL] [Abstract][Full Text] [Related]
26. Exposure-response of 1,2:3,4-diepoxybutane-specific N-terminal valine adducts in mice and rats after inhalation exposure to 1,3-butadiene.
Georgieva NI; Boysen G; Bordeerat N; Walker VE; Swenberg JA
Toxicol Sci; 2010 Jun; 115(2):322-9. PubMed ID: 20176624
[TBL] [Abstract][Full Text] [Related]
27. Characterization of urinary metabolites from Sprague-Dawley rats and B6C3F1 mice exposed to [1,2,3,4-13C]butadiene.
Nauhaus SK; Fennell TR; Asgharian B; Bond JA; Sumner SC
Chem Res Toxicol; 1996 Jun; 9(4):764-73. PubMed ID: 8831821
[TBL] [Abstract][Full Text] [Related]
28. Hemoglobin adducts and micronuclei in rodents after treatment with isoprene monoxide or butadiene monoxide.
Fred C; Grawé J; Törnqvist M
Mutat Res; 2005 Aug; 585(1-2):21-32. PubMed ID: 15925539
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the disposition of butadiene epoxides in Sprague-Dawley rats and B6C3F1 mice following a single and repeated exposures to 1,3-butadiene via inhalation.
Thornton-Manning JR; Dahl AR; Bechtold WE; Griffith WC; Henderson RF
Toxicology; 1997 Nov; 123(1-2):125-34. PubMed ID: 9347927
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of cancer tests of 1,3-butadiene using internal dose, genotoxic potency, and a multiplicative risk model.
Fred C; Törnqvist M; Granath F
Cancer Res; 2008 Oct; 68(19):8014-21. PubMed ID: 18829559
[TBL] [Abstract][Full Text] [Related]
31. A novel DNA adduct, originating from 1,2-epoxy-3,4-butanediol, is the major DNA adduct after exposure to [2,3-(14)C]-1,3-butadiene,[4-(14)C]-1,2-epoxy-3-butane.
Boogaard PJ; van Sittert NJ; Watson WP; de Kloe KP
Chem Biol Interact; 2001 Jun; 135-136():687-93. PubMed ID: 11397423
[TBL] [Abstract][Full Text] [Related]
32. HPLC-ESI+-MS/MS analysis of N7-guanine-N7-guanine DNA cross-links in tissues of mice exposed to 1,3-butadiene.
Goggin M; Loeber R; Park S; Walker V; Wickliffe J; Tretyakova N
Chem Res Toxicol; 2007 May; 20(5):839-47. PubMed ID: 17455958
[TBL] [Abstract][Full Text] [Related]
33. Genetic effects of 1,3-butadiene and associated risk for heritable damage.
Pacchierotti F; Adler ID; Anderson D; Brinkworth M; Demopoulos NA; Lähdetie J; Osterman-Golkar S; Peltonen K; Russo A; Tates A; Waters R
Mutat Res; 1998 Jan; 397(1):93-115. PubMed ID: 9463556
[TBL] [Abstract][Full Text] [Related]
34. Dose responses for the formation of hemoglobin adducts and urinary metabolites in rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-(14)C]-butadiene.
Booth ED; Kilgour JD; Watson WP
Chem Biol Interact; 2004 Mar; 147(2):213-32. PubMed ID: 15013822
[TBL] [Abstract][Full Text] [Related]
35. Research strategy for assessing target tissue dosimetry of 1,3-butadiene in laboratory animals and humans.
Bond JA; Csanády GA; Leavens T; Medinsky MA
IARC Sci Publ; 1993; (127):45-55. PubMed ID: 8070886
[TBL] [Abstract][Full Text] [Related]
36. Characterization of glycidol-hemoglobin adducts as biomarkers of exposure and in vivo dose.
Honda H; Törnqvist M; Nishiyama N; Kasamatsu T
Toxicol Appl Pharmacol; 2014 Mar; 275(3):213-20. PubMed ID: 24467927
[TBL] [Abstract][Full Text] [Related]
37. First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice.
Filser JG; Faller TH; Bhowmik S; Schuster A; Kessler W; Pütz C; Csanády GA
Chem Biol Interact; 2001 Jun; 135-136():249-65. PubMed ID: 11397395
[TBL] [Abstract][Full Text] [Related]
38. 1,3-Butadiene: I. Review of metabolism and the implications to human health risk assessment.
Kirman CR; Albertini RJ; Sweeney LM; Gargas ML
Crit Rev Toxicol; 2010 Oct; 40 Suppl 1():1-11. PubMed ID: 20868266
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of N-terminal valine peptide adducts specific for 1,2-epoxy-3-butene.
Georgieva NI; Boysen G; Upton PB; Jayaraj K; Gold A; Swenberg JA
Chem Biol Interact; 2007 Mar; 166(1-3):219-25. PubMed ID: 16860298
[TBL] [Abstract][Full Text] [Related]
40. Parallelogram based approach for in vivo dose estimation of genotoxic metabolites in humans with relevance to reduction of animal experiments.
Motwani HV; Frostne C; Törnqvist M
Sci Rep; 2017 Dec; 7(1):17560. PubMed ID: 29242644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
